Gerald Oliver
Family Medicine · Lenexa, KSNPI 1407843865
Payments from drug & device makers
Across 232 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$939
- Lilly USA, LLC$589
- Novo Nordisk$448
- Amgen$394
- Biohaven Pharmaceutical Holding Company Ltd.$245
- Abbott$205
- plus $778 from 21 others
What the payments were for
- Food & beverage$3,56599%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $939 |
| Lilly USA, LLC | 38 | $589 |
| Novo Nordisk | 30 | $448 |
| Amgen | 18 | $394 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $245 |
| Abbott | 13 | $205 |
| GSK | 3 | $125 |
| Johnson & Johnson | 6 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Boehringer Ingelheim | 4 | $67 |
| Novartis | 4 | $49 |
| Bayer | 2 | $47 |
| Antares Pharma, Inc. | 2 | $36 |
| AstraZeneca | 3 | $36 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Pfizer | 2 | $26 |
| Biogen | 1 | $21 |
| Organogenesis Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Merck | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- SHINGRIX$101
How this compares
$3,597 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 15 | $1,063 |
| Ezetimibe | 20 | $587 |
| Atorvastatin Calcium | 40 | $430 |
| Fenofibrate | 17 | $386 |
| Rosuvastatin Calcium | 27 | $328 |
| Amlodipine Besylate | 44 | $295 |
| Tamsulosin Hcl | 14 | $280 |
| Potassium Chloride | 12 | $267 |
| Lisinopril | 26 | $228 |
| Pioglitazone Hcl | 13 | $202 |
| Losartan Potassium | 20 | $170 |
| Levothyroxine Sodium | 14 | $125 |
| Metformin Hcl ErMetformin Hcl | 16 | $120 |
| Simvastatin | 11 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $939 | $1,06315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Lenexa
- Daniel DickersonLenexa$13.6M
- Casey JohnsonLenexa$499K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.